AbbVie Inc

NYSE:ABBVUnited States

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It also offers investigational asset named NX-13, oral NLRX1 agonist (a member of the NOD-like receptor family), which is in Phase II for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).

Contact Information

Headquarters

1 N Waukegan RdNORTH CHICAGO, IL, United States 60064

Phone

847-932-7900

Fax

302-655-5049

Executives

Executive Chairman of the Board

Richard Gonzalez

Chief Executive Officer, Director

Robert Michael

Chief Financial Officer, Executive Vice President

Scott Reents

Chief Human Resource Officer, Executive Vice President

Timothy Richmond

Executive Vice President, General Counsel, Company Secretary

Perry Siatis